AK111

DRUG6 trials

Sponsors

Akeso

Conditions

Ankylosing SpondylitisHealthy SubjectsPsoriasisSkin Diseases

Phase 1

A Study of AK111 in Subjects With Moderate-to-severe Plaque Psoriasis

CompletedNCT05504317

Start: 2020-05-28End: 2021-03-02Updated: 2025-03-05

A Clinical Study of AK139 in Healthy Subjects

Not yet recruitingNCT06947109

AkesoHealthy Subjects

Start: 2025-05-06End: 2026-01-30Target: 48Updated: 2025-04-27

Phase 2

A Study to Evaluate the Efficacy and Safety of AK111 in Subjects With Active Ankylosing Spondylitis

CompletedNCT05467995

AkesoAnkylosing Spondylitis

Start: 2021-06-02End: 2022-05-19Updated: 2024-03-06

To Evaluate the Efficacy and Safety of AK111 Injection in the Treatment of Moderate to Severe Plaque Psoriasis

CompletedNCT06061471

AkesoPsoriasis, Skin Diseases

Start: 2023-09-22End: 2024-12-11Updated: 2025-01-23

Phase 3

A Study to Evaluate the Efficacy and Safety of AK111 in Subjects With Moderate to Severe Plaque Psoriasis

CompletedNCT06066125

AkesoPsoriasis, Skin Diseases

Start: 2023-03-31End: 2024-08-19Updated: 2025-02-20

A Phase III Study to Evaluate the Efficacy and Safety of AK111 in Subjects With Active Ankylosing Spondylitis

CompletedNCT06378697

AkesoAnkylosing Spondylitis

Start: 2023-11-22End: 2025-11-07Updated: 2026-03-18

Related Papers

Efficacy, Safety and Pharmacokinetics of IL-17 Monoclonal Antibody Injection (AK111) in Patients with Moderate-to-Severe Plaque Psoriasis: A Randomized, Double-Blinded, Placebo-Controlled Phase Ib Multidose Escalation Clinical Study

Dermatology and Therapy2022-12-243 citations